FDA Scientists Raise Questions About Duchenne Drug

FDA scientists challenge clinical trial data for deramiocel, a stem cell therapy for Duchenne muscular dystrophy, stating the drug failed to meet its primary endpoint in phase III trials despite researchers' contrary claims presented at the American Academy of Neurology annual meeting.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.